Lonza Group AG LONN.SW
Composite 47/100; the shares have moved about 23% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 26/100 — a moderate mark against it.
Balance-sheet strength ranks 58/100 — a slight point in its favour. Momentum ranks 57/100 — a slight point in its favour. Income ranks 52/100 — a slight point in its favour.
Valuation ranks 26/100 — a moderate mark against it. Growth ranks 48/100 — a slight mark against it. Quality ranks 48/100 — a slight mark against it.
What the company does Lonza Group AG is a Swiss contract development and manufacturing organization serving pharma and biotech clients globally across biologics, small molecules, and specialized modalities such as cell & gene, microbial, bioscience, and mRNA platforms.
Key financials Revenue grew 11.2% and EPS 39.2%, with ROE 12.9%, ROA 5.4%, and ROCE 16.4%. Margins: gross 37.1%, operating 23.4%, net −1.6%. Debt/equity 0.51, net debt/EBITDA 1.54, interest coverage 7.93, current ratio 1.66.
Stock health Sideravia scores: Quality 59.5, Growth 59.3, Strength 64.8, Valuation 41.3, Momentum 59.2, Income 51.1. Piotroski F-Score 8/9, Altman Z 4.36. RSI(14) 61.60; 3m momentum 20.33%.
Price vs fair value The stock trades at a PREMIUM of 50.20% versus our fair-value estimate and at a discount of 18.42% versus the analyst 12-month target. - High forward P/E 30.12 and PEG 1.51 (Valuation percentile 41.3/100) - Negative FCF yield −3.9% and high P/B 4.81 - Net margins −1.6% despite strong revenue growth 11.2% - RSI 61.60 indicates mildly overbought conditions
Looking forward Analysts expect 680.70 as a 12-month target, implying 18.42% upside from the current price, supported by growth in biologics and specialized modalities.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.